Cleveland Clinic cardiologist Dr. A. Michael Lincoff is part of a new nine-member medical advisory board at Regado Biosciences, a New Jersey company developing quickly reversible anti-clotting drugs.
Lincoff is the director of the Clinic’s Coordinating Center for Clinical Research and its Center for Clinical Research. He is also vice chairman of both the Lerner Research Institute and the department of cardiovascular medicine.
The medical board will advise Regado on its clinical programs and guide the commercialization of its primary product: the REG1 anticoagulation system, which the company says can help with heart problems including acute coronary syndrome. Regado also hopes it can replace standard heparin therapy during some balloon angioplasties and stentings.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Regado is preparing a Phase IIb study for later this year. Its investors include Domain Associates, Quaker BioVentures, Aurora Funds and Caxton Advantage Life Sciences Fund.
